352 related articles for article (PubMed ID: 18288643)
1. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
2. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.
Skelding KA; Barry RD; Shafren DR
Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
Au GG; Lincz LF; Enno A; Shafren DR
Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
Skelding KA; Barry RD; Shafren DR
Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
[TBL] [Abstract][Full Text] [Related]
8. Oncolysis of human ovarian cancers by echovirus type 1.
Shafren DR; Sylvester D; Johansson ES; Campbell IG; Barry RD
Int J Cancer; 2005 Jun; 115(2):320-8. PubMed ID: 15688406
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
[TBL] [Abstract][Full Text] [Related]
10. Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer.
Haley ES; Au GG; Carlton BR; Barry RD; Shafren DR
J Mol Med (Berl); 2009 Apr; 87(4):385-99. PubMed ID: 19139835
[TBL] [Abstract][Full Text] [Related]
11. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
12. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
14. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.
Nakamori M; Fu X; Pettaway CA; Zhang X
Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
Cozzi PJ; Burke PB; Bhargav A; Heston WD; Huryk B; Scardino PT; Fong Y
Prostate; 2002 Oct; 53(2):95-100. PubMed ID: 12242723
[TBL] [Abstract][Full Text] [Related]
17. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A
Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820
[TBL] [Abstract][Full Text] [Related]
18. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
